Unbound Prime | Journal of Infectious Diseases

(Journal of Infectious Diseases[TA])

31,732 results

An Intracisternal Rabbit Model Reveals Treponema pallidum Egress Across an Intact Blood-Brain Barrier. [Journal Article]
J Infect Dis. 2026 Jul 16. [Online ahead of print]Fan SH, Xie L, … Lin LRJI
CONCLUSIONS: T. pallidum can disseminate from the CNS to peripheral tissues without disrupting BBB integrity, as evidenced by systemic seroconversion, peripheral T. pallidum DNA detection, and stable QAlb. This challenges the view that BBB disruption is required for spirochetal traversal and highlights non-disruptive egress pathways.
Publisher Full Text (DOI)

Impact of early antiretroviral treatment on tissue resident memory CD4+ T cells in the gastrointestinal tract. [Journal Article]
J Infect Dis. 2026 Jul 16. [Online ahead of print]Vimonpatranon S, Ssemaganda A, … RV254/SEARCH010 and RV304/SEARCH013 study groups JI
CONCLUSIONS: Sigmoid CD4+ TRM may be early mucosal targets of HIV-1 infection and that their persistent depletion contributes to decreased mucosal barrier function, warranting development of therapeutic strategies that can restore CD4+ TRM during HIV treatment.
Publisher Full Text (DOI)

Multibead-based immunoassay provides one-step species-specific serodiagnosis of filarial infections and Strongyloides stercoralis in travelers and immigrants. [Journal Article]
J Infect Dis. 2026 Jul 15. [Online ahead of print]Yu M, Kubofcik J, … Nutman TBJI
CONCLUSIONS: These data provide a new framework for clinically useful parasite-specific serology that helps to direct targeted therapeutic options.
Publisher Full Text (DOI)

Afucosylated VAR2CSA-Specific IgG Reduces Risks of Placental Malaria. [Journal Article]
J Infect Dis. 2026 Jul 14. [Online ahead of print]Ding H, Lloyd Williams OH, … Rogerson SJJI
CONCLUSIONS: Afucosylated IgG to VAR2CSA, measured by FEASI or mass spectrometry, was a correlate of protection from placental malaria, and afucosylated IgG activated NK cells and neutrophils. Naturally acquired or therapeutic afucosylated IgG antibody could have a role in protection from malaria infection.
Publisher Full Text (DOI)

Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. [Journal Article]
J Infect Dis. 2026 Jul 14. [Online ahead of print]Borriello F, Koh GCKW, … De Alwis DPJI
CONCLUSIONS: The data support exploring GB-0669 at 1200 mg in a Phase 2 trial for treating COVID-19 in immunocompromised individuals. The combination of GB-0669 with antiviral drugs may offer additional therapeutic benefits.
Publisher Full Text (DOI)

Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy. [Journal Article]
J Infect Dis. 2026 Jul 14. [Online ahead of print]Peng Q, Wong YC, … Jin XJI
CONCLUSIONS: ICVAX was well-tolerated and elicited robust antigen-specific T-cell responses in ART-suppressed people with HIV-1. Its efficacy will be assessed in future studies.
Publisher Full Text (DOI)

Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis. [Journal Article]
J Infect Dis. 2026 Jul 11. [Online ahead of print]Kawai N, Bando T, … Ikematsu HJI
CONCLUSIONS: Prior-season infection was associated with enhanced VE of current-season vaccination and similar ARs among vaccinated individuals, whereas prior-season vaccination was associated with attenuated but effective VE. These findings highlight the importance of interpreting AR alongside VE, as ARs reflect differences in baseline risk.
Publisher Full Text (DOI)

Protective effects of influenza B neuraminidase antibodies against symptomatic influenza virus infection. [Journal Article]
J Infect Dis. 2026 Jul 10. [Online ahead of print]Rogers S, Sumner KM, … Martin ETJI
CONCLUSIONS: NAI antibodies were a strong correlate of protection against symptomatic IBV infection, with protective effects independent of those from HAI antibodies. These findings suggest the use and standardization of neuraminidase content in influenza vaccines could provide broader protection against influenza.
Publisher Full Text (DOI)

The Effect of Prevaccination Analgesics on Influenza Vaccine Immunogenicity and Effectiveness. [Journal Article]
J Infect Dis. 2026 Jul 10. [Online ahead of print]Skellington CN, Schmidt K, … Colombo REJI
CONCLUSIONS: These findings suggest acetaminophen and/or nonsteroidal anti-inflammatory analgesic use within 24 hours before influenza vaccination does not reduce vaccine immunogenicity or effectiveness in adults.
Publisher Full Text (DOI)

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age. [Journal Article]
J Infect Dis. 2026 Jul 09. [Online ahead of print]Desai M, Jimenez G, … Priddy FJI
CONCLUSIONS: mRNA-1345 revaccination at 24 months was well-tolerated and elicited nAb responses non-inferior to primary vaccination. Based on nAb titers comparable to those after primary vaccination, mRNA-1345 revaccination has the potential to provide extended protection against RSV disease once timing for revaccination is determined. Clinical Trials Registration. NCT05127434 (https://clinicaltrials.gov/study/NCT05127434).
Publisher Full Text (DOI)

Epidemiology and molecular evolution of norovirus GII.17 in the United States, 2021-2025. [Journal Article]
J Infect Dis. 2026 Jul 08. [Online ahead of print]Barclay L, Wikswo ME, … Chhabra PJI
CONCLUSIONS: These findings indicate a recent shift in norovirus genotype dominance in the U.S., likely driven by enhanced transmissibility or population susceptibility rather than increased virulence. Continued molecular surveillance is essential to monitor viral evolution and public health impact of norovirus.
Publisher Full Text (DOI)

Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies-United States, 2017-March 2020. [Journal Article]
J Infect Dis. 2026 Jul 08. [Online ahead of print]Lutz CS, Castro-Roman P, … Anderson TCJI
CONCLUSIONS: Nationally, seroprevalence for MeV, MuV, RuV, and VZV antibodies remains high among persons aged 6-59 years and our findings indicate robust antibody responses are maintained decades after vaccination or natural infection. Maintaining high population immunity through vaccination is critical to prevent cases and outbreaks of all four vaccine-preventable diseases.
Publisher Full Text (DOI)

Log in to Prime